Getting Patients Started
Krystal Connect provides personalized patient support for your patients during their VYJUVEK treatment journey
The first step to getting your patients started on VYJUVEK via Krystal Connect is to download and fill out the Krystal Connect Enrollment Form.
Download Form
To contact Krystal Connect, please call 1-844-5-KRYSTAL or use our Connect With Us form.
Services Include:
Educating patients about VYJUVEK and living with dystrophic epidermolysis bullosa (DEB)
- Answer patient questions about VYJUVEK
- Provide resources and help connect patients with programs about DEB and VYJUVEK
Providing insurance coverage support
- Assist with the insurance process, including benefits investigation and prior authorizations
- Informing patients about potential financial assistance options and eligibility requirements as needed
Supporting with treatment logistics
- Helping patients evaluate appropriate administration site options, either in a healthcare professional setting or in a home setting
- Sharing information with patients about what to expect, and helping coordinate weekly treatments
Krystal Biotech has partnered with Option Care Health® to provide convenient in-home weekly VYJUVEK administration to your patients.
View Additional Helpful Forms and Resources
Discover ResourcesVYJUVEK is a topical gel indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII (COL7A1) gene.
WARNINGS AND PRECAUTIONS
Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds for approximately 24 hours following treatment. Wear protective gloves when assisting subjects with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.
Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.
Dispose all materials (e.g., vial, syringe, needle, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard bag or container.
ADVERSE REACTIONSThe most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.
- Please see Important Safety Information above and click here for full Prescribing Information.
VYJUVEK is a topical gel indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII (COL7A1) gene.
WARNINGS AND PRECAUTIONS
Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds for approximately 24 hours following treatment. Wear protective gloves when assisting subjects with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.
Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.
Dispose all materials (e.g., vial, syringe, needle, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard bag or container.
ADVERSE REACTIONSThe most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.
- Please see Important Safety Information above and click here for full Prescribing Information.
You are about to leave the VYJUVEKHCP.com website
Are you sure you want to leave?